Evaxion A (EVAX) - News Archive

Revolutionizing Cancer Treatment: Evaxion s AI-designed Vaccine Achieves Breakthrough Results In a remarkable stride for cancer treatment, Evaxion A/S, a clinical-stage TechBio leader, has announced unprecedented effica...

Breakthrough in Cancer Research: Evaxion to Unveil Promising Phase 2 Trial Results of AI-Powered Vaccine at ESMO Congress 2025 COPENHAGEN, Denmark, October 13, 2025 In a promising leap forward in the fight against cance...

Evaxion A/S Finalizes Strategic Debt-to-Equity Conversion with European Investment Bank COPENHAGEN, Denmark, July 11, 2025 In a significant financial maneuver that signals its steadfast commitment to innovation and grow...

Evaxion Biotech: Pioneering AI-Driven Vaccination Strategies in 2025 In a world grappling with unprecedented health challenges, the emergence of innovative biotechnologies has never been more critical. At the forefront...

Evaxion Biotech Announces 2024 Financial Results Amid Challenging Industry Landscape COPENHAGEN, Denmark Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage TechBio company at the forefront of developing AI-Immunology...

Evaxion Biotech Secures $10.8 Million in Public Offering Amidst Strategic Milestones and Nasdaq ChallengesCOPENHAGEN, Denmark January 31, 2025 In a significant leap forward, Evaxion Biotech A/S (NASDAQ: EVAX), a pioneer...

Copenhagen, Denmark January 10, 2025: In a strategic move reflecting its adaptive approach to market dynamics, Evaxion Biotech A/S (NASDAQ: EVAX) has announced an amendment to the ratio of its American Depositary Shares...

Progressing Towards Innovation: Evaxion Biotech Aims High with 2025 MilestonesCOPENHAGEN, Denmark, December 9, 2024 In a significant stride within the biotechnological sphere, Evaxion Biotech A/S (NASDAQ: EVAX) has unve...

In a strategic move to strengthen its market presence, Evaxion Biotech A/S (NASDAQ: EVAX), a Copenhagen-based clinical-stage TechBio company renowned for its pioneering AI-Immunology powered vaccine development, has ann...

Pioneering the Future of Healthcare: How Evaxion and NobleAI Are Shaping a New Era of AI-Driven InnovationIn the rapidly evolving landscape of biotechnology and artificial intelligence, two companies are making signific...

In a significant move that could reshape its financial standing and operational capacity, Evaxion Biotech A/S (NASDAQ: EVAX), a Copenhagen-based innovator in AI-powered vaccine technology, is actively negotiating a tran...

Resilience in the Face of Adversity: Evaxion Biotech’s Battle to Retain Nasdaq ListingIn a developing narrative of corporate resilience, Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage TechBio firm known for levera...

In the constantly evolving field of biopharmaceuticals, the integration of artificial intelligence (AI) in drug development has emerged as a pivotal trend. Evaxion Biotech, a pioneer in AI-immunology platforms, has made...

Evaxion Expands Strategic Partnership with MSD to Enhance AI-Driven Vaccine DevelopmentIn a significant advancement for vaccine innovation, Evaxion Biotech A/S, a clinical-stage TechBio company renowned for its pioneeri...

Evaxion Biotech A/S Unveils Enhanced AI-Immunology Platform for Superior Vaccine Antigen Prediction COPENHAGEN, Denmark, Sept. 19, 2024 Evaxion Biotech A/S (NASDAQ: EVAX), a leading clinical-stage TechBio company specia...

In the ever-evolving landscape of cancer treatment, personalization has become a focal point for researchers and clinicians alike. Evaxion Biotech A/S, a pioneering company at the intersection of artificial intelligence...

COPENHAGEN, Denmark September 9, 2024 Evaxion Biotech A/S, a pioneering clinical-stage TechBio company renowned for its expertise in AI-driven immunology, has announced significant progress in its vaccine development pi...

Evaxion Biotech A/S Announces Completion of ADS Ratio Change: A Step Towards Increased Shareholder ValueEvaxion Biotech A/S, a leading TechBio company specializing in AI-Immunology powered vaccines, recently made a sign...

Evaxion Biotech A/S, a leading clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, has recently published data from its Phase 1 dose escalation study of EVX-01, its personalized can...

In a groundbreaking development, Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage TechBio company specializing in AI-Immunology powered vaccines, presented compelling immune data from its ongoing Phase 2 study at th...